PDF
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Attana AB ("Attana") hereby announces that it has signed a heads of terms agreement regarding the development and supply of novel proteins from ExpreS[2]ion Biotechnologies ApS ("ExpreS[2]ion"). The first target protein will be the ExpreS[2]ion-produced SARS-CoV-2 spike and receptor-binding-domain (RBD) antigen used in ExpreS[2]ion's COVID-19 vaccine program. Attana will now be able to offer customers utilising its AVA diagnostic platform, this and other novel ExpreS[2]ion proteins. The parties are not disclosing the commercial terms of the agreement.
In early June, ExpreS[2]ion announced (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-that-the-cvlp-covid-19-vaccine-shows-strong-virus-neutralization-properties-in-,c3131028) that the capsid virus-like particle (cVLP) COVID-19 vaccine being developed by ExpreS[2]ion and its joint venture partner AdaptVac demonstrated excellent COVID-19 immunization with a very high level of SARS-CoV-2 virus neutralization in a mice model, thus reaching an important pre-clinical milestone ahead of schedule.
Attana assisted in the preclinical development of the vaccine by performing various studies on ExpreS[2]ion's novel antigen in its Attana Virus Analytics diagnostic platform (AVA) using the novel ExpreS[2]ion protein. By applying the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (developed by ExpreS[2]ion) and anti-IgG antibodies, the Attana AVA platform successfully identified:
1. Degree of non-specific immune system response
2. Relative concentration of specific antibodies
3. Quality of specific antibodies
4. Relative concentration of SARS-CoV-2 IgG antibodies
Based on this positive outcome, ExpreS[2]ion and Attana have now agreed on commercial terms of a development and supply agreement that will enable Attana AVA customers to use this, and other ExpreS[2]ion-produced proteins.
ExpreS[2]ion's CEO Bent Frandsen comments:
"It is promising that we are able to increase the availability and usability of our SARS-CoV-2 antigen, and other ExpreS[2]ion-produced proteins, by signing this agreement with Attana. It will hopefully increase the attractiveness of both companies in the diagnostic sector. Based on the successful utilisation of the AVA platform in our COVID-19 vaccine program, it is also of interest to us to deepen our relationship with Attana considering our ambition to further broaden and advance our project pipeline."
Attana's CEO Teodor Aastrup comments:
"The AVA platform in combination with the novel SARS-CoV-2 antigen developed by ExpreS[2]ion has been shown to provide valuable insights into the immunological response to COVID-19. Having worked together with ExpreS[2]ion during the past few months, we are happy to today announce this agreement and look forward to also jointly developing additional novel proteins to broaden the application areas of our AVA platform."
About ExpreS[2]ion
ExpreS[2]ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS[2]ion Biotech Holding AB with company register number 559033-3729. ExpreS[2]ion has developed a unique technology platform, ExpreS[2], for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS[2] is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS[2]ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.